Indication

HIBERIX is indicated for active immunization as a booster dose for the prevention of invasive disease caused by Haemophilus influenzae type b (Hib). HIBERIX is approved for use in children 15 months through 4 years of age (prior to fifth birthday).

Important Safety Information

• In clinical studies, adverse events in children receiving HIBERIX included pain and redness at the injection site, fever, fussiness, loss of appetite, and restlessness
• A severe allergic reaction (eg, anaphylaxis) after a previous dose of any Hib or tetanus toxoid-containing vaccine or any component of HIBERIX is a contraindication
• If Guillain-Barré syndrome has occurred within 6 weeks of receipt of a prior vaccine containing tetanus toxoid, the decision to give HIBERIX should be based on potential benefits and risks
• Vaccination with HIBERIX may not protect 100% of susceptible individuals

References: 1. Prescribing Information for HIBERIX.